Spots Global Cancer Trial Database for tcr
Every month we try and update this database with for tcr cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM) | NCT05549297 | Advanced Melano... | Tebentafusp Tebentafusp wit... Investigators C... | 18 Years - | Immunocore Ltd | |
| Creating an Innovative AI-based Technology TCRact for Designing and Optimizing T-cell Receptors (TCR) for Use in Cancer Immunotherapies | NCT04994093 | Colon Cancer Cancer | Collection of b... | 18 Years - | Ardigen | |
| E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers | NCT05686226 | Cervical Cancer Throat Cancer Oropharynx Canc... Anal Cancer Vulva Cancer Vaginal Cancer Penile Cancer Metastatic Canc... HPV-Related Mal... HPV-Related Car... HPV-Related Cer... HPV-Related Squ... HPV-Related Ade... HPV Positive Or... HPV-Associated ... HPV-Related Ade... HPV-Related End... HPV-Related Ana... HPV-Related Pen... HPV-Related Vul... HPV Positive Re... | E7 TCR-T cells | 18 Years - | Rutgers, The State University of New Jersey | |
| CRTE7A2-01 TCR-T Cells for HPV-16 Positive Advanced Cancers | NCT06358053 | Cervical Cancer Anal Cancer Head and Neck C... Other Solid Tum... | CRTE7A2-01 TCR-... | 18 Years - 65 Years | Corregene Biotechnology Co., Ltd | |
| Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies | NCT00496860 | Progressive Met... | ALT-801 | 18 Years - | Altor BioScience | |
| Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma | NCT03070392 | Uveal Melanoma | IMCgp100 Dacarbazine Ipilimumab Pembrolizumab | 18 Years - 99 Years | Immunocore Ltd | |
| Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma | NCT03070392 | Uveal Melanoma | IMCgp100 Dacarbazine Ipilimumab Pembrolizumab | 18 Years - 99 Years | Immunocore Ltd | |
| QUILT-2.008: Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma | NCT01029873 | Metastatic Mela... | Cisplatin ALT-801 | 18 Years - | Altor BioScience | |
| Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers | NCT05296564 | Sarcoma, Synovi... Sarcoma,Soft Ti... Melanoma Stage ... Triple Negative... Metastatic Canc... Non Small Cell ... Bladder Urothel... Neuroblastoma, ... Ovary Cancer | CYCLOPHOSPHAMID... Cyclophosphamid... HBI 0201-ESO TC... Aldesleukin | 18 Years - 70 Years | Hadassah Medical Organization | |
| To Explore the Feasibility of Dynamic Changes of TCR Diversity in Peripheral Blood in Monitoring Recurrence and Evaluating Prognosis of Epithelial Ovarian Cancer | NCT06315270 | Epithelial Ovar... Stage III Ovari... Stage IV Ovaria... | 18 Years - 75 Years | The First Hospital of Jilin University | ||
| A Cohort IND Expanded Access Program for Supporting Patient Access to Tebentafusp | NCT04960891 | Uveal Melanoma | Tebentafusp | 18 Years - | Immunocore Ltd | |
| MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies | NCT05735717 | Hematologic Mal... Acute Leukemia Remission Acute Myeloid L... Acute Lymphobla... AML TP53 Intrachromosoma... Cytogenetic Abn... CNS Leukemia Minimal Residua... Myelodysplasia Juvenile Myelom... Somatic Mutatio... PTPN11 Gene Mut... N-RAS Gene Ampl... Neurofibromatos... NF1 Mutation CBL Gene Mutati... Monosomy 7 Chromosome Abno... Fetal Hemoglobi... | Fludarabine Busulfan Melphalan Rituximab Levetiracetam | - 60 Years | Masonic Cancer Center, University of Minnesota |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
